SynAct Pharma announces Notice of Allowance of a US patent covering the resomelagon tablet

The Notice of Allowance concludes the examination of the patent application, which is allowed for issuance as a patent, which with the immediate payment of the issue fee is expected to be granted within a few weeks. The granted formulation patent will substantially strengthen SynAct’s proprietary rights with respect to the clinical dosage form of resomelagon, the most advanced drug candidate in SynAct’s portfolio.

“The Notice of Allowance is an important step in SynAct’s strategy to strengthen the intellectual property protection around resomelagon. It reflects our diligent efforts to execute on the overall strategy to protect key assets in our development program” said Thomas Boesen, Chief Operating Officer of SynAct Pharma.

SynAct has previously announced issuance of U.S. patent 12,239,631 and U.S. patent 12,661,336, both of which cover the crystal form of resomelagon, the latter with a patent term adjustment extending the term of that patent until July 2, 2044. The favorable PTAB decision previously announced, and the resulting Notice of Allowance add another important element to SynAct’s overall intellectual property strategy for resomelagon, providing an additional layer of protection extending to June 2042 (PTA not yet determed).

Resomelagon (AP1189 acetate) is SynAct’s lead drug candidate and is being developed as an oral, once-daily selective melanocortin agonist across two main development tracks: rheumatoid arthritis (RA) and host-directed therapy in viral infections. In RA, resomelagon is being evaluated as a combination with first-line methotrexate therapy, while in viral infections SynAct is evaluating resomelagon’s potential to resolve excessive inflammation in patients with severe viral disease, including respiratory viral infections and Dengue.